Crucell and DSM Biologics Announce PER.C6(R) Licensing Agreement with UMN Pharma (Market Wire via Yahoo! Finance)
Leiden/Sittard, The Netherlands, March 9, 2006 - Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6 research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6 cell line in its 'UMN-03' project, which aims to employ a fusion protein in